Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.
作者信息
McKelvie R S, Benedict C R, Yusuf S
机构信息
Department of Medicine, Division of Cardiology, McMaster University, Hamilton Health Sciences Corporation-General Division, 237 Barton Street East, Hamilton, ON, Canada L8L 2X2.
出版信息
BMJ. 1999 May 22;318(7195):1400-2. doi: 10.1136/bmj.318.7195.1400.
Abstract
摘要
相似文献
1
Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.循证心脏病学：充血性心力衰竭的预防及无症状左心室功能障碍的管理
BMJ. 1999 May 22;318(7195):1400-2. doi: 10.1136/bmj.318.7195.1400.
2
Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction.
Am J Cardiol. 2001 Dec 1;88(11):1298-300. doi: 10.1016/s0002-9149(01)02092-6.
3
ACE inhibitors in patients with minimal or asymptomatic left ventricular dysfunction.轻度或无症状左心室功能不全患者使用血管紧张素转换酶抑制剂。
Coron Artery Dis. 1995 Apr;6(4):288-94. doi: 10.1097/00019501-199504000-00004.
4
The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening.“无症状”左心室收缩功能障碍的流行病学：对筛查的启示
Ann Intern Med. 2003 Jun 3;138(11):907-16. doi: 10.7326/0003-4819-138-11-200306030-00012.
5
6
ACE inhibitors: myocardial infarction and congestive heart failure.血管紧张素转换酶抑制剂：心肌梗死与充血性心力衰竭
Am Fam Physician. 1995 Nov 1;52(6):1801-6.
7
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).血管重建术后血管紧张素转换酶抑制研究（APRES）
J Am Coll Cardiol. 2000 Mar 15;35(4):881-8. doi: 10.1016/s0735-1097(99)00634-8.
8
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.老年患者用药证据不断增加的影响 第2部分。心力衰竭和心血管高危患者使用的血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Br J Clin Pharmacol. 2006 May;61(5):502-12. doi: 10.1111/j.1365-2125.2006.02610.x.
9
Summaries for patients. Screening for asymptomatic heart failure.
Ann Intern Med. 2003 Jun 3;138(11):I51. doi: 10.7326/0003-4819-138-11-200306030-00005.
10
Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects.常规超声心动图筛查无症状左心室功能障碍在儿童癌症幸存者中的应用：基于模型的临床和经济效果评估。
Ann Intern Med. 2014 May 20;160(10):661-71. doi: 10.7326/M13-2266.
引用本文的文献
1
Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California.加州平价医疗法案实施后青少年和青年淋巴瘤患者的诊断时分期和生存情况。
Int J Cancer. 2022 Apr 1;150(7):1113-1122. doi: 10.1002/ijc.33880. Epub 2021 Dec 8.
2
Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.用于评估心肌活力的正电子发射断层扫描：一项基于证据的分析。
Ont Health Technol Assess Ser. 2005;5(16):1-167. Epub 2005 Oct 1.
3
Heart failure.心力衰竭
BMJ Clin Evid. 2011 Aug 30;2011:0204.
4
Heart failure.心力衰竭
BMJ Clin Evid. 2010 Feb 25;2010:0204.
5
[Validity and usefulness of B-type natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care].B型利钠肽（BNP）在基层医疗中对高危患者左心室功能障碍早期检测的有效性和实用性
Aten Primaria. 2012 Jan;44(1):13-9. doi: 10.1016/j.aprim.2010.12.009. Epub 2011 Jun 1.
6
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.加拿大心血管学会2007年心力衰竭最新共识会议建议：预防、并发疾病或急性失代偿期间的管理以及生物标志物的应用。
Can J Cardiol. 2007 Jan;23(1):21-45. doi: 10.1016/s0828-282x(07)70211-8.
7
[Brain natriuretic peptide in primary care: diagnostic value in heart failure].[基层医疗中的脑钠肽：对心力衰竭的诊断价值]
Aten Primaria. 2005 Nov 30;36(9):510-4. doi: 10.1016/s0212-6567(05)70554-0.
8
Do statins prevent heart failure in patients after myocardial infarction?他汀类药物能否预防心肌梗死后患者发生心力衰竭？
Curr Heart Fail Rep. 2004 Dec;1(4):156-60. doi: 10.1007/s11897-004-0003-x.
9
Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?β受体阻滞剂是否应用于治疗小儿慢性心力衰竭患者？
Paediatr Drugs. 2002;4(12):771-8. doi: 10.2165/00128072-200204120-00001.
10
Prevention of heart failure.心力衰竭的预防。
Curr Cardiol Rep. 2002 May;4(3):194-9. doi: 10.1007/s11886-002-0050-4.
本文引用的文献
1
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.辛伐他汀对冠心病患者心力衰竭发生率的影响。
J Card Fail. 1997 Dec;3(4):249-54. doi: 10.1016/s1071-9164(97)90022-1.
2
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.降血压治疗主要随机试验的前瞻性协作综述方案。世界卫生组织 - 国际高血压学会降血压治疗试验协作组
J Hypertens. 1998 Feb;16(2):127-37.
3
Biochemical detection of left-ventricular systolic dysfunction.左心室收缩功能障碍的生化检测
Lancet. 1998 Jan 3;351(9095):9-13. doi: 10.1016/s0140-6736(97)03034-1.
4
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.利钠肽在基层医疗中评估可能患有新发心力衰竭患者的价值。
Lancet. 1997 Nov 8;350(9088):1349-53. doi: 10.1016/S0140-6736(97)06031-5.
5
Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population.城市人群中的有症状和无症状左心室收缩功能障碍
Lancet. 1997 Sep 20;350(9081):829-33. doi: 10.1016/S0140-6736(97)03033-X.
6
Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.无心肌梗死人群的左心室扩张与充血性心力衰竭风险
N Engl J Med. 1997 May 8;336(19):1350-5. doi: 10.1056/NEJM199705083361903.
7
8
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.血浆去甲肾上腺素在无症状左心室功能不全患者中的预后意义。SOLVD研究人员。
Circulation. 1996 Aug 15;94(4):690-7. doi: 10.1161/01.cir.94.4.690.
9
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.糖尿病是左心室功能障碍研究（SOLVD）试验和注册研究中发病率和死亡率的一个预测指标。
Am J Cardiol. 1996 May 1;77(11):1017-20. doi: 10.1016/s0002-9149(97)89163-1.
10
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.HOPE（心脏结局预防评估）研究：一项针对心血管事件高危患者的大型、简易随机试验的设计，该试验旨在研究血管紧张素转换酶抑制剂（雷米普利）和维生素E。HOPE研究调查人员。
Can J Cardiol. 1996 Feb;12(2):127-37.
Zotero 插件